Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol CD36 contributors: mct/pgu - updated : 02-04-2016
HGNC name CD36 molecule (thrombospondin receptor)
HGNC id 1663
ASSOCIATED DISORDERS
corresponding disease(s) CD36D
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
constitutional       loss of function
in insulin resistance
constitutional     --low  
in PWS point to an abnormal control of lipid and glucose homeostasis which may explain the insatiable hunger in these patients
constitutional     --low  
reduced the capability of monocytes to phagocyte apoptotic neutrophils
Susceptibility
  • to severe malaria, cerebral form
  • to atherosclerosis
  • to insulin resistance
  • to hypertension
    • Variant & Polymorphism SNP
  • 14T/C and 53G/T increase the risk of cerebral malaria
  • AGGIG haplotype modulating lipid metabolism and cardiovascular risk
  • mutations within the kidney can increase blood pressure
  • SNPs of CD36 are associated with metabolic syndrome in Puerto Ricans
    • Candidate gene
  • high soluble CD36 is associated with increased type 2 diabetes risk
  • involved in sterile inflammation through assembly of TLR4/TLR6 heterodimer in atherosclerosis and Alzeihmer's disease
    • Marker
    Therapy target
    SystemTypeDisorderPubmed
    cardiovascularaquired 
    target for treatment and/or prevention of cardiovascular disease
    diabetetype 2 
    novel therapeutic strategies aimed at reducing CD36-mediated fatty acids uptake show promise for the prevention or treatment of cardiac dysfunction related to obesity and diabetes
    diabetetype 2 
    novel and potential therapeutic target for diabetic renal tubule fibrosis
    neurologyneurodegenerativealzheimer
    potential therapeutical target to counteract the cerebrovascular dysfunction associated with APP.
    neurologyneurodegenerative 
    is a putative therapeutic target for cerebral amyloid angiopathy (CAA)
    ANIMAL & CELL MODELS
  • CD36 is necessary for the development of lipotoxic cardiomyopathy in MHC-PPARalpha mice
  • Cd36 deletion ameliorates cerebrovascular function in Tg2576 mice at an age marked by extensive amyloid deposition in brain and cerebral blood vessels